Barua Pranoy, O'Mahony M Sinead
University Department of Geriatric Medicine, Academic Centre, Llandough Hospital, Cardiff, United Kingdom.
Drugs Aging. 2005;22(12):1029-59. doi: 10.2165/00002512-200522120-00004.
Asthma is under-recognised and undertreated in older populations. This is not surprising, given that one-third of older people experience significant breathlessness. The differential diagnosis commonly includes asthma, chronic obstructive pulmonary disease (COPD), heart failure, malignancy, aspiration and infections. Because symptoms and signs of several cardiorespiratory diseases are nonspecific in older people and diseases commonly co-exist, investigations are important. A simple strategy for the investigation of breathlessness in older people should include a full blood count, chest radiograph, ECG, peak flow diary and/or spirometry with reversibility as a minimum. If there are major abnormalities on the ECG, an echocardiogram should also be performed. Diurnal variability in peak flow readings >or=20% or >or=15% reversibility in forced expiratory volume in 1 second, spontaneously or with treatment, support a diagnosis of asthma. Distinguishing asthma from COPD is important to allow appropriate management of disease based on aetiology, accurate prediction of treatment response, correct prognosis and appropriate management of the chest condition and co-morbidities. The two conditions are usually readily differentiated by clinical features, particularly age at onset, variability of symptoms and nocturnal symptoms in asthma, supported by the results of reversibility testing. Full lung function tests may not necessarily help in differentiating the two entities, although gas transfer factor is characteristically reduced in COPD and usually normal or high in asthma. Methacholine challenge tests previously mainly used in research are now also used widely and safely to confirm asthma in clinical settings. Interest in exhaled nitric oxide as a biomarker of airways inflammation is increasing as a noninvasive tool in the diagnosis and monitoring of asthma. Regular inhaled corticosteroids (ICS) are the mainstay of treatment of asthma. Even in mild disease in older adults, regular preventive treatment should be considered, given the poor perception of bronchoconstriction by older asthmatic patients. If symptoms persist despite ICS, addition of long-acting beta(2)-adrenoceptor agonists (LABA) should be considered. Addition of LABA to ICS improves asthma control and allows reduction in ICS dose. However, older people have been grossly under-represented in trials of LABA, many trials having excluded those >or=65 years of age. On meta-analysis, beta(2)-adrenoceptor agonists (both short acting and long acting) are associated with increased cardiovascular mortality and morbidity in asthma and COPD. While the evidence for excess cardiovascular mortality is stronger for short-acting beta(2)-adrenoceptor agonists, it would be prudent to exercise particular care in using beta(2)-adrenoceptor agonists (long acting and short acting) in those at risk of adverse cardiovascular outcomes, including older people. Regular review of cardiovascular status (and monitoring of serum potassium concentration) in patients taking beta(2)-adrenoceptor agonists is crucial. The response to LABA should be carefully monitored and alternative 'add-on' therapy such as leukotriene receptor antagonists (LRA) should be considered. LRA have fewer adverse effects and in individual cases may be more effective and appropriate than LABA. Long-term trials evaluating beta(2)-adrenoceptor agonists and other bronchodilator strategies are needed particularly in the elderly and in patients with cardiovascular co-morbidities. There is no evidence that addition of anticholinergics improves control of asthma further, although the role of long-acting anticholinergics in the prevention of disease progression is currently being researched. Older patients need to be taught good inhaler technique to improve delivery of medications to lungs, minimise adverse effects and reduce the need for oral corticosteroids. Nurse-led education programmes that include a written asthma self-management plan have the potential to improve outcomes.
哮喘在老年人群中未得到充分认识和治疗。鉴于三分之一的老年人有明显的气促症状,这并不奇怪。鉴别诊断通常包括哮喘、慢性阻塞性肺疾病(COPD)、心力衰竭、恶性肿瘤、误吸和感染。由于几种心肺疾病的症状和体征在老年人中不具有特异性且疾病常并存,因此进行检查很重要。针对老年人气促进行检查的一个简单策略应至少包括全血细胞计数、胸部X光片、心电图、峰流速日记和/或肺功能测定及可逆性检测。如果心电图有重大异常,还应进行超声心动图检查。峰流速读数的日变化率≥20%或一秒用力呼气容积的可逆性≥15%(自发或经治疗后)支持哮喘的诊断。区分哮喘和COPD对于根据病因进行适当的疾病管理、准确预测治疗反应、正确判断预后以及对胸部疾病和合并症进行适当管理很重要。这两种疾病通常可通过临床特征,特别是发病年龄、症状变异性和哮喘的夜间症状,结合可逆性检测结果很容易区分。尽管气体交换因子在COPD中通常降低而在哮喘中通常正常或升高,但完整的肺功能测试不一定有助于区分这两种疾病。以前主要用于研究的乙酰甲胆碱激发试验现在也在临床环境中广泛且安全地用于确诊哮喘。作为气道炎症生物标志物的呼出一氧化氮作为一种非侵入性工具在哮喘诊断和监测中的应用越来越受到关注。规律吸入糖皮质激素(ICS)是哮喘治疗的主要方法。鉴于老年哮喘患者对支气管收缩的感知较差,即使是老年成人的轻度疾病,也应考虑进行规律的预防性治疗。如果尽管使用了ICS症状仍持续,应考虑加用长效β2肾上腺素受体激动剂(LABA)。将LABA加用至ICS可改善哮喘控制并允许减少ICS剂量。然而,老年人在LABA试验中的代表性严重不足,许多试验排除了年龄≥65岁的患者。荟萃分析表明,β2肾上腺素受体激动剂(短效和长效)与哮喘和COPD患者心血管死亡率和发病率增加相关。虽然短效β2肾上腺素受体激动剂导致心血管死亡率过高的证据更强,但对于有不良心血管结局风险的人群,包括老年人,谨慎使用β2肾上腺素受体激动剂(长效和短效)是明智的。对服用β2肾上腺素受体激动剂的患者定期复查心血管状况(并监测血清钾浓度)至关重要。应仔细监测对LABA的反应,并考虑使用替代的“附加”疗法,如白三烯受体拮抗剂(LRA)。LRA的不良反应较少,在个别情况下可能比LABA更有效和合适。尤其需要针对老年人和有心血管合并症的患者进行评估β2肾上腺素受体激动剂和其他支气管扩张剂策略的长期试验。虽然长效抗胆碱能药物在预防疾病进展中的作用目前正在研究,但没有证据表明加用抗胆碱能药物能进一步改善哮喘控制。需要教导老年患者良好的吸入器使用技术,以改善药物输送至肺部的效果,将不良反应降至最低,并减少口服糖皮质激素的需求。由护士主导的教育项目,包括书面的哮喘自我管理计划,有可能改善治疗效果。